The Brand New Era of C1-Esterase Inhibitor Deficiency Therapy
by Carol on 16. Aug, 2011 in Health
Abstract&preditary angioedema (HAE) is definitely an autosomal dominant disorder scientifically indicated by recurrent instances of angioedema.
Until late-2008, HAE therapy within the U . s . States was largely restricted to antifibrinolytic agents or attenuated androgens.
Although these drugs slow up the number and harshness of angioedema attacks, they're connected with significant dose-related
negative effects. Recent advances have significantly transformed the control over HAE. Consequently, we're starting on the fresh era
for treating this problem which includes effective on-demand management of attacks in addition to effective prophylactic treatment.
Herein we discuss the different treatments for C1-inhibitor deficiency, concentrating on fresh developments and literature released
in the last... More details: Full article...
Tags: HAE, treatment, treatment options, prophylactic treatment, united states, Health
Related posts:
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented At 2011 American Academy Of Allergy Asthma & Immunology (AAAAI) Annual Meeting ViroPharma Incorporated (Nasdaq: VPHM) today announced data presented in two...
Bench to bedside review: The role of C1-esterase inhibitor in sepsis and other critical illnesses The complement system plays a crucial role in the body's...
Autoimmune Angioedema And Its Effects? There are many types of angioedema that are described in...
Santarus And Pharming Announce RHUCIN Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting Specialty biopharmaceutical corporation Santarus, Inc. (NASDAQ:SNTS) and biotech corporation Pharming...
Santarus And Pharming Announce RHUCIN Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting Specialty biopharmaceutical corporation Santarus, Inc. (NASDAQ:SNTS) and biotech corporation Pharming...
Related posts brought to you by Yet Another Related Posts Plugin.